Catalyst Wire Dossier Catalyst Wire Dossier

Olopatadine 0.2%

olopatadine hydrochloride · Alcon Research
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Olopatadine 0.2%, covering 2017-08-14 to 2022-12-15. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment [Phase 4]

See pricing